Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 8;9(1):e83750.
doi: 10.1371/journal.pone.0083750. eCollection 2014.

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV

Christopher J Hoffmann  1 , Richard E Chaisson  1 , Neil A Martinson  2
Affiliations

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV

Christopher J Hoffmann et al. PLoS One. .

Abstract

Objectives: Many randomized and cohort studies have reported a survival benefit with cotrimoxazole prophylaxis without detecting a difference in tuberculosis (TB) incidence by cotrimoxazole status. However, several in vitro studies have reported that cotrimoxazole possesses anti-TB activity. We sought to compare TB incidence and TB diagnostic yield by cotrimoxazole use among participants in a well characterized cohort of HIV-infected adults living in a high TB prevalence region.

Methods: We analyzed prospective data from a long-term longitudinal cohort of adults receiving HIV care and TB investigations in Soweto, South Africa. Using longitudinal analysis, we compared total and laboratory confirmed TB incidence by cotrimoxazole status as well as all-cause mortality. In addition, we compared TB culture results by cotrimoxazole status.

Results: In a multivariable analysis, adjusted for sex, body mass index, WHO clinical stage, time-updated CD4 count, and antiretroviral therapy status, we observed an association between cotrimoxazole and an increase in TB incidence (hazard ratio 1.7, 95% CI: 1.2, 2.2). However, when restricted to laboratory-confirmed TB, there was no association between cotrimoxazole and TB incidence (hazard ratio: 0.97, 95% CI: 0.39, 2.4). In TB cases, we found no difference in the proportion of positive sputum cultures or days to culture positivity by cotrimoxazole status. Cotrimoxazole was associated with a reduction in mortality.

Conclusions: In this cohort with a mortality benefit from cotrimoxazole, we found an increased risk of all TB among individuals using cotrimoxazole, likely a result of residual confounding, but no association between use of cotrimoxazole and laboratory-confirmed TB. Cotrimoxazole did not compromise TB diagnosis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

References

    1. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, et al. (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997–1998. IntJ TubercLung Dis 6: 55–63. - PubMed
    1. Martinson NA, Hoffmann CJ, Chaisson RE (2011) Epidemiology of tuberculosis and HIV: recent advances in understanding and responses. ProcAm ThoracSoc 8: 288–293. - PMC - PubMed
    1. World Health Organization (2012) Global tuberculosis report 2012. Geneva, Switzerland. WHO/HTM/TB/2012.6 WHO/HTM/TB/2012.6.
    1. Sesay M, Chimzizi R, Chotpitayasunondh T, Crowley S, Duncombe C, et al.. (2006) Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents, and adults in resource-limited settings. Geneva, Switzerland: WHO. Available: http://www.who.int/hiv/pub/guidelines/ctx/en/. Accessed 2013 Nov 30.
    1. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silverman ML, et al. (2009) Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 53: 4789–4793. - PMC - PubMed

Publication types

Substances